Literature DB >> 27237418

Seizure Correlates with Prolonged Hospital Stay, Increased Costs, and Increased Mortality in Nontraumatic Subdural Hematoma.

Jacob R Joseph1, Brandon W Smith1, Craig A Williamson1, Paul Park2.   

Abstract

BACKGROUND: Nontraumatic subdural hematoma (NTSDH) is a common neurosurgical disease process, with mortality reported as high as 13%. Seizure has a known association with NTSDH, although patient outcomes have not previously been well studied in this population. The purpose of this study was to examine the relationship between in-hospital seizure and inpatient outcomes in NTSDH.
METHODS: Using the University HealthSystem Consortium (UHC) database, we performed a retrospective cohort study of adults with a principal diagnosis of NTSDH (International Classification of Diseases, Ninth Revision code 43.21) between 2011 and 2015. Patients with in-hospital seizure (International Classification of Diseases, Ninth Revision codes 34500-34591, 78033, 78039) were compared with those without. Patients with a history of seizure before arrival were excluded. Patient demographics, hospital length of stay (LOS), intensive care unit stay, in-hospital mortality, and direct costs were recorded.
RESULTS: A total 16,928 patients with NTSDH were identified. Mean age was 69.2 years, and 64.7% were male. In-hospital seizure was documented in 744 (4.40%) patients. Hospital LOS was 17.64 days in patients with seizure and 6.26 days in those without (P < 0.0001). Mean intensive care unit stay increased from 3.36 days without seizure to 9.36 days with seizure. In-hospital mortality was 9.19% in patients without seizure and 16.13% in those with seizure (P < 0.0001). Direct costs were $12,781 in patients without seizure and $38,110 in those with seizure (P < 0.0001).
CONCLUSIONS: Seizure in patients with NTSDH correlates with significantly increased total LOS and increased mortality. Direct costs are similarly increased. Further studies accounting for effects of illness severity are necessary to validate these results.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epilepsy; Nontraumatic; Seizure; Subdural hematoma

Mesh:

Year:  2016        PMID: 27237418     DOI: 10.1016/j.wneu.2016.05.033

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  3 in total

1.  Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals.

Authors:  Silky Beaty; Ning A Rosenthal; Julie Gayle; Prashant Dongre; Kristen Ricchetti-Masterson
Journal:  Front Neurol       Date:  2021-11-29       Impact factor: 4.003

2.  In-hospital mortality rates, complication rates, length of stay, and total costs of >14,000 chronic subdural hematomas treated in the U.S. between 2016 and 2020: Query of the premier health-care database.

Authors:  Philipp Hendrix; Oded Goren; Shamsher Dalal; Ulrick Sidney Kanmounye; Gregory M Weiner; Clemens M Schirmer; Itay Melamed
Journal:  Surg Neurol Int       Date:  2022-08-19

3.  Epidemiology and injectable antiseizure medication treatment patterns of seizure patients treated in United States hospitals.

Authors:  Silky Beaty; Ning Rosenthal; Julie Gayle; Prashant Dongre; Kristen Ricchetti-Masterson; Denise H Rhoney
Journal:  Front Neurol       Date:  2022-09-12       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.